Drilldown: Medicines

Codeine (2)

Other values:

Search

None (32) · (multiple, generic dominant) (1) · Alfenta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Heroin (1) · Krokodil (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Stablon (1) · Stadol (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vicodin (1) · Zyprexa (oral, IM acute), Zyprexa Zydis (ODT), Zyprexa Relprevv (LAI), Lybalvi (with samidorphan) (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · Contains LSA (2) · Contains mescaline (2)

Other values:

Search

None (49) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1)

None (49) · Adult: 15–60 mg every 4 hours as needed. (1) · Schizophrenia / acute mania: 5-10 mg PO once daily, target 10-15 mg/day. Acute agitation IM: 10 mg, may repeat in 2 hours. Relprevv LAI: 150-300 mg every 4 weeks after oral overlap (1)

None (49) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1) · Tablets 2.5, 5, 7.5, 10, 15, 20 mg; ODT (Zydis) 5, 10, 15, 20 mg; acute IM injection 10 mg/vial; Relprevv LAI 210, 300, 405 mg vials (1)

None (49) · 20 mg/day (oral) (1) · 360 mg/day (1)

None (49) · intramuscular (acute and long-acting) (1) · Oral (1) · PO (only formulation marketed in the US). (1)

None (49) · 30–60 min (PO) (1) · Sedation from first dose; neuroleptic effect emerges over days to weeks (1)

None (49) · 24 hours (oral); 2-4 weeks (LAI) (1) · 4–6 hours (1)

None (49) · 2.5–3 hours (1) · 21-54 hours'"`UNIQ--ref-00000026-QINU`"' (1)

None (49) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~60% (oral); ~100% (IM)'"`UNIQ--ref-00000027-QINU`"' (1)

None (49) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Signal for gestational diabetes and metabolic syndrome with maternal exposure; the metabolic load can be substantial during pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (50) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)